fbpx Skip to main content

Under-enrollment in clinical trials can significantly impact the development of appropriate treatment options, reducing the validity of researched outcomes. In many cases, it can also result in the early termination of the research studies themselves. This study, published in the Journal of Neuro-Oncology, analyzes the impact of race/ethnicity and socioeconomic status on enrollment rates in glioma clinical trials.

The study used data from 988 patients. The rate at which the patients enrolled in clinical trials was analyzed. The researchers found that 43.6% of glioma patients were screened for trials, and 17.5% were enrolled. Among the group analyzed, 33% were part of a designated minority group, with 19.6% being Asian/Pacific Islander.

It was determined that race/ethnicity, insurance type, median household income, percent below the poverty line, and socioeconomic status were not correlated with trial enrollment. Only distance to the hospital, in-state location, and WHO grade were associated with enrollment at initial diagnosis and recurrence.

The researchers concluded that race and socioeconomic status do not impact enrollment rates when it comes to glioma clinical trials. However, these factors combined with proximity to care centers and tumor grade may be an important consideration. Therefore, they concluded that patients should be screened for these qualities to allow a more inclusive group of patients to participate in these trials [1].


[1] Morshed, R. A., Reihl, S. J., Molinaro, A. M., Kakaizada, S., Young, J. S., Schulte, J. D., Butowski, N., Taylor, J., Bush, N. A., Aghi, M. K., Berger, M. S., Chang, S., Clarke, J., & Hervey-Jumper, S. L. (2020). The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. Journal of Neuro-Oncology, 148(1), 131–139. https://doi.org/10.1007/s11060-020-03503-x

You May Also Like::  Indigenous Populations Underrepresented in Alzheimer’s Disease Clinical Trials